Results 51 to 60 of about 73,607 (303)
Drugs in Context, 2020 The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK–signal transducers and activators of transcription pathway, where cytokine receptor signaling takes ...
Novin Nezamololama +3 more
doaj +1 more source
Management of MPN beyond JAK2 [PDF]
Hematology, 2014 Abstract Thrombocytosis has a large number of potential underlying causes, but the dominant group of hematological conditions for consideration in this setting are the myeloproliferative neoplasms (MPNs). In this chapter, we consider several key linked questions relating to the management of thrombocytosis in MPNs and discuss several ...
Claire N, Harrison +1 more
openaire +2 more sources
Iraqi Journal of Hematology, 2020 BACKGROUND: Chronic inflammation has been suggested to contribute to the pathogenesis of thrombosis in polycythemia vera (PV) as it triggers in vivo activation of platelets, leukocytes, and endothelial cells, which are all of major importance during ...
Ibrahim Abdullah Mahmood +2 more
doaj +1 more source
The human myeloproliferative disorders: molecular pathogenesis and clonal heterogeneity
, 2010 The classical myeloproliferative disorders (MPD), comprising essential thrombocythaemia (ET), polycythaemia vera (PV) and idiopathic myelofibrosis (IMF), are clonal premalignant haematopoietic neoplasms associated with activating mutations in signalling ...
core +1 more source
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. [PDF]
, 2021 Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes efficacy.
Levine, Ross L +14 more
core +1 more source
PLoS ONE, 2022 JAK2 is cytokine-activated non-receptor tyrosine kinase. Although JAK2 is mainly localized at the plasma membrane, it is also present on the centrosome. In this study, we demonstrated that JAK2 localization to the centrosome depends on the SH2 domain and
Aashirwad Shahi +3 more
doaj +1 more source
Downregulation of ClC-2 by JAK2 [PDF]
Cellular Physiology and Biochemistry, 2012 JAK2 (Janus kinase-2) is activated by cell shrinkage and may thus participate in cell volume regulation. Cell volume regulatory ion channels include the small conductance Cl(-) channels ClC-2. The present study thus explored whether JAK2 influences ClC-2 activity.
Hosseinzadeh, Zohreh +2 more
openaire +3 more sources
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele. [PDF]
PLoS ONE, 2013 Utilizing ENU mutagenesis, we identified a mutant mouse with elevated platelets. Genetic mapping localized the mutation to an interval on chromosome 19 that encodes the Jak2 tyrosine kinase.
Nicole M Anderson +16 more
doaj +1 more source
Rewriting the mechanism of JAK2 activation [PDF]
Cell Cycle, 2015 Class I cytokine receptors regulate a wide range of clinically relevant cellular processes. This family of receptors contains around 30 members including receptors for erythropoietin (EPO), prolactin (PRL), growth hormone (GH), thrombopoietin (TPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), leukemia inhibitory factor (LIF), interleukin-
Brooks, Andrew J., Waters, Michael J.
openaire +5 more sources
Aging Is a Key Driver for Adult Acute Myeloid Leukemia
Aging and Cancer, EarlyView.Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley +1 more source